Method for treating TTP with a single variable immunoglobulin domain, and its use
The use of a polypeptide targeting vWF with ISVDs addresses the limitations of current TTP treatments by directly inhibiting platelet aggregation, leading to faster recovery and reduced complications, thus improving patient outcomes.
Patent Information
- Application Number
- JP2022110921
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-07-30
- Filing Date
- 2022-07-11
- Publication Date
- 2026-07-01
- Estimated Expiration
- 2035-06-16
AI Technical Summary
Current treatments for thrombotic thrombocytopenic purpura (TTP), such as plasma exchange and transfusions, require multiple sessions over several days without direct pharmacological targeting of the active process of ULvWF-mediated platelet aggregation, leading to significant mortality and morbidity risks, and there is a need for improved therapeutic approaches.
Administration of a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand factor (vWF) to directly inhibit the formation of persistent small thrombi and platelet consumption in the microvascular system, allowing for more rapid control of the thrombotic process and reducing the need for plasma exchanges and transfusions.
The polypeptide significantly reduces time to response, decreases exacerbations, lowers morbidity and mortality, and minimizes complications associated with plasma exchanges and transfusions, providing a safer and more effective treatment for TTP.